Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 6/20 | 0.57 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 4/20 | 0.40 |
| ▸ | MME | P08473 | 3/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 3/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993834 | 1.00 | METAP1 (0.57) | METAP1METAP2RIPK1ACEMME | |
| SCHEMBL1993833 | 1.00 | METAP1 (0.57) | METAP1METAP2RIPK1ACEMME | |
| SCHEMBL12625243 | 0.88 | METAP1 (0.44) | METAP1METAP2RIPK1ACEMME | |
| SCHEMBL1997944 | 0.88 | METAP1 (0.44) | METAP1METAP2RIPK1ACEMME | |
| SCHEMBL1997942 | 0.88 | METAP1 (0.44) | METAP1METAP2RIPK1ACEMME | |
| SCHEMBL12569138 | 0.88 | RIPK1 (0.44) | METAP1RIPK1ACEMMESCN9A | |
| SCHEMBL1997047 | 0.88 | RIPK1 (0.44) | METAP1RIPK1ACEMMESCN9A | |
| SCHEMBL1997050 | 0.88 | RIPK1 (0.44) | METAP1RIPK1ACEMMESCN9A | |
| SCHEMBL4508566 | 0.88 | METAP1 (0.53) | METAP1METAP2ACEMMEXIAP | |
| SCHEMBL4508570 | 0.88 | METAP1 (0.53) | METAP1METAP2ACEMMEXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960373-B2 | 2-alkoxy-3,4,5-trihydroxyalkylamide-benzothiazepines preparation thereof, compositions containing them and use thereof | SANOFI-AVENTIS (FR) | 2011-06-14 | — | — | US | claimed |
| EP-2029596-B1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZOTHIAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI AVENTIS (FR) | 2010-02-24 | — | — | EP | claimed |
| US-20090093459-A1 | 2-ALKOXY-3,4,5-TRIHYDROXYALKYLAMIDE-BENZOTHIAZEPINES PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | claimed |
| US-7960373-B2 | 2-alkoxy-3,4,5-trihydroxyalkylamide-benzothiazepines preparation thereof, compositions containing them and use thereof | SANOFI-AVENTIS (FR) | 2011-06-14 | — | — | US | disclosed |
| US-20090093459-A1 | 2-ALKOXY-3,4,5-TRIHYDROXYALKYLAMIDE-BENZOTHIAZEPINES PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093459-A1 | 2-ALKOXY-3,4,5-TRIHYDROXYALKYLAMIDE-BENZOTHIAZEPINES PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093459-A1 | 2-ALKOXY-3,4,5-TRIHYDROXYALKYLAMIDE-BENZOTHIAZEPINES PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | TPH2, CYP4B1, HTR3C | METAP1 3151/4885METAP2 1946/4885RIPK1 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.